![CCO Oncology Podcast artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts124/v4/3b/39/f2/3b39f298-5635-0bd6-df15-80fecdd32562/mza_3001520250050155739.jpg/100x100bb.jpg)
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
CCO Oncology Podcast
English - September 28, 2022 16:10 - 29 minutes - 27.3 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:
• Identifying patients who may benefit the most from adjuvant osimertinib
• Testing for EGFR mutations in early-stage NSCLC
• Critical importance of getting molecular test results before starting immunotherapy
• Monitoring cardiac toxicity in patients receiving osimertinib
• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib
Presenters:
Ryan D. Gentzler, MD, MS
Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Virginia
Thoracic Medical Oncologist
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Jonathan Riess, MD, MS
Associate Professor
Department of Internal Medicine/Hematology-Oncology
University of California, Davis
Medical Director, Thoracic Oncology
University of California, Davis Comprehensive Cancer Center
Sacramento, California
Link to full program:
https://bit.ly/3DZGzSO